REG - Glanbia PLC - Statement on Equity Placement

GlanbiaAnnouncement

30/09/2025 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250930:nRSd4774Ba&default-theme=true

RNS Number : 4774B  Glanbia PLC  30 September 2025

Glanbia plc

Statement on Equity Placement

Glanbia plc, the Better Nutrition company ("Glanbia" or "the Company"), has
been informed by Tirlán Co-operative Society Limited ("Tirlán") that it
intends to sell up to 17,000,000 ordinary shares (the "Equity Placement
Shares") in Glanbia in order to finance the concurrent repurchase of Tirlán's
outstanding €250 million 1.875 per cent Secured Exchangeable Bonds, due 27
January 2027 (ISIN: XS2436579978). The Equity Placement Shares represent
approximately 7% of Glanbia's share capital.

The Equity Placement Shares are being offered to institutional investors by
way of an accelerated bookbuild offering (the "Equity Placement"). Goodbody
Stockbrokers UC ("Goodbody") and J&E Davy ("Davy") are acting as joint
global coordinators and joint bookrunners in connection with the Equity
Placement (Goodbody and Davy together the "Joint Global Coordinators").
Coöperatieve Rabobank U.A. in cooperation with Kepler Cheuvreux S.A.
("Rabobank-Kepler Cheuvreux") will act as joint bookrunner in connection with
the Equity Placement (together with Goodbody and Davy, the "Joint
Bookrunners").

Glanbia plc confirms it intends to participate in the Equity Placement by
purchasing up to 45% of the Equity Placement Shares, subject to a maximum
value of €100 million (the "plc Participation Amount"). Any shares purchased
by the Company through this placement will be cancelled. The Board has
approved a €50 million share buyback, additional to the €100 million
authorised in February this year, to cover the plc Participation Amount. 1 

Glanbia has entered into an agreement with Davy to act as principal in
relation to the purchase of the Company's Shares from the Equity Placement,
within certain pre-set parameters. This share buyback programme may be
conducted by way of block trades in accordance with the Company's general
authority to repurchase shares. The Company confirms that it currently has no
unpublished inside information.

Glanbia's participation in the Equity Placement will be conducted within the
limitations of the Company's general authority to repurchase shares as set out
in Resolution 10 approved by the Company's shareholders at the 2025 Annual
General Meeting on 30 April 2025 and up to a maximum of 10% of the issued
share capital of the Company (being 25,634,283 ordinary shares which has been
reduced to 21,245,761 ordinary shares following the completion of the latest
buyback programme). Unless renewed, this authority will expire on the earlier
of the close of business on the date on which the next Annual General Meeting
of the Company is held in 2026 (expected to be in April 2026) or 31 July 2026.

Further details Glanbia's participation in the Equity Placement, including the
value of the plc Participation Amount, will be published once the transaction
has completed.

ENDS

 

For further information contact:

Glanbia plc
 
+353 56 777 2200

Mark Garvey, Chief Financial Officer

Liam Hennigan, Group Secretary & Head of Investor Relations:
            +353 86 046 8375

Martha Kavanagh, Director of Corporate Affairs:
                         +353 87 646 2006

Davy

Ivan Murphy
 
    +353 1 679 7788

 

 

 1  In February 2025, Glanbia announced that its Board had approved a €100
million buyback authorisation. On 22 September Glanbia completed a €50
million share buyback programme under this authority.  On 30 September 2025
the Board approved increasing this buyback authorisation by €50 million to
fulfil Glanbia's participation in the Equity Placement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLMMATMTIJBIA